PremiumRatingsMerck & Company: Buy Rating Backed by Growth Prospects in Cardiopulmonary and Infectious Disease Franchises Merck announces Health Canada approval for KEYTRUDA in cervical cancer Veeva announces Merck committed to Veeva Vault CRM PremiumThe FlyFDA willing to trade faster drug reviews for lower prices, Bloomberg reports Merck’s Bravecto Quantum parasiticide for dogs approved by FDA Merck price target lowered to $98 from $99 at Morgan Stanley PremiumThe FlyVerona Pharma downgraded to Equal Weight from Overweight at Wells Fargo Verona Pharma downgraded to Hold from Buy at TD Cowen Nvidia hits $4T market cap, Merck acquires Verona Pharma: Morning Buzz 
